


FORM PTO-1390 (Modified) (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				016777/0436	
				U.S. APPLICATION NO. (known), see 37 C.F.R. 1.53 Unassigned	
INTERNATIONAL APPLICATION NO. <b>PCT/CA99/00376</b>		INTERNATIONAL FILING DATE <b>26/April/1999</b>		PRIORITY DATE CLAIMED <b>28/April/1998</b>	
TITLE OF INVENTION <b>PROTEIN FORMULATIONS</b>					
APPLICANT(S) FOR DO/EO/US Martin BILLGER and Mikael BRULLS					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4	<input type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.			
5	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
	<input type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).			
	<input checked="" type="checkbox"/>	has been transmitted by the International Bureau.			
	<input type="checkbox"/>	is not required, as the application was filed in the United States Receiving Office (RO/US)			
6	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).			
7	<input checked="" type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).			
	<input type="checkbox"/>	have been transmitted by the International Bureau.			
	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.			
	<input checked="" type="checkbox"/>	have not been made and will not be made.			
8	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9	<input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10	<input type="checkbox"/>	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern other document(s) or information included:					
11	<input type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12	<input type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13	<input checked="" type="checkbox"/>	A FIRST preliminary amendment.			
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.			
14	<input type="checkbox"/>	A substitute specification.			
15	<input type="checkbox"/>	A change of power of attorney and/or address letter.			
16	<input type="checkbox"/>	Other items or information:			

U.S. APPLICATION NO. (If known, see 37 CFR 1.50) <b>Unassigned 097674002</b>		INTERNATIONAL APPLICATION NO <b>PCT/CA99/00376</b>		ATTORNEY'S DOCKET NUMBER <b>016777/0436</b>	
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b>	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....\$860.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) .....\$690.00					
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$710.00					
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$1,000.00					
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) .....\$100.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$860.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	18	-	20	= 0	\$18.00
Independent Claims	2	-	3	= 0	\$80.00
Multiple dependent claim(s) (if applicable)				\$270.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$860.00</b>	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$0.00	
<b>SUBTOTAL =</b>				<b>\$860.00</b>	
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
<b>TOTAL NATIONAL FEE =</b>				<b>\$860.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
<b>TOTAL FEES ENCLOSED =</b>				<b>\$860.00</b>	
				Amount to be: refunded \$	
				charged \$	
<p>a. <input checked="" type="checkbox"/> A check in the amount of <b>\$860.00</b> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed.</p>					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109 <b>October 24, 2000</b>			SIGNATURE  NAME <b>STEPHEN A. BENT</b> REGISTRATION NUMBER <b>29,768</b>		

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Martin BILLGER et al.  
Title: PROTEIN FORMULATIONS  
Appl. No.: Unassigned  
Filing Date: October 24, 2000  
Examiner: Unassigned  
Art Unit: Unassigned

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Preliminary to examination, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please amend the claims as follows:

Claim 3, line 1, delete "to 2".

Claim 4, line 1, delete "any one of claims 1 to 3" and insert --claim 1,--.

Claim 6, line 1, delete "any one of claims 1 to 5" and insert --claim 1,--.

Claim 7, line 1, delete "any one of claims 1 to 6" and insert --claim 1,--.

Claim 8, line 1, delete "any one of claims 1 to 7" and insert --claim 1,--.

Claim 9, line 1, delete "any one of claims 1 to 8" and insert --claim 1,--.

Claim 10, line 1, delete "any one of claims 1 to 9" and insert --claim 1,--.

Claim 11, line 1, delete "any one of claims 1 to 9" and insert --claim 1, --.

Claim 12, line 1, delete "any one of claims 1 to 11" and insert --claim 1--.

Claim 13, line 1, delete "any one of claims 1 to 11" and insert --claim 1--.

Claim 14, line 1, delete "any one of claims 1 to 11" and insert --claim 1--.

Claim 17, line 3, delete "any one of claims 1 to 11" and insert --claim 1--.

**REMARKS**

The claims have been amended to delete improper multiple dependencies and phrases that do not conform with U.S. patent practice. The claims are fully supported by the specification and original claims. Examination and allowance of these claims is earnestly requested.

Respectfully submitted,

Date October 24, 2000

By



FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5404  
Facsimile: (202) 672-5399

Stephen A. Bent  
Attorney for Applicant  
Registration No. 29,768

002.403674.1

PROTEIN FORMULATIONS

## TECHNICAL FIELD

5 The present invention relates to pharmaceutical formulations comprising human parathyroid hormone (PTH), useful for the treatment of bone related disorders such as osteoporosis.

## 10 BACKGROUND ART

*Parathyroid hormone*

15 Human parathyroid hormone is an 84 amino acid protein involved in calcium and phosphorus homeostasis and control of bone growth and density. Equivalent terms for parathyroid hormone is PTH and the less frequently used parathyrin and parathormone.

Human PTH may be obtained through tissue extraction, from peptide synthesis or from genetically engineered yeast, bacterial or mammalian cell hosts. Essentially pure human  
20 PTH is disclosed in US 5,208,041. Recombinant production of PTH in *E. coli* is disclosed e.g. in US 5,223,407, US 5,646,015 and US 5,629,205. Production of recombinant human PTH in yeast is disclosed in EP-B-0383751. Synthetic human PTH is commercially available from Bachem Inc., Bubendorf, Switzerland.

25 In mammals, the balance between bone formation, associated with the activity of osteoblasts, on one hand, and bone loss, associated with the activity of osteoclasts, on the other hand, is disturbed in several bone affecting diseases, such as osteoporosis.

Parathyroid hormone has been shown to have a potential therapeutic role in osteoporosis.

The anabolic actions of parathyroid hormone on bone are reviewed by Dempster, D.W. *et al.* in Endocrine reviews vol. 14(6), 690-709, 1993.  
30

For many proteins it is common that increasing the protein concentration increases the propensity for protein aggregation and precipitation, either specific or non-specific. Such reactions may be rapid, or may proceed slowly, so the aggregation may not always be clearly evident. In addition, high protein concentrations may reveal small but significant autocatalytic activities, that increases protein degradation. Regardless, aggregation and precipitation affect not only the available protein drug concentration but also the physical and biopharmaceutical properties of the formulation. From a pharmaceutical point of view, this is highly undesirable. A common prejudice is therefore to keep protein concentrations low.

It is known that PTH forms aggregates when the concentration is increased. One strategy to overcome this problem is to modify pH to either very low or very high values. However, this often stimulates chemical degradation of the protein, and further adds to discomfort during administration, e.g. subcutaneous injection.

Dilute formulations necessitates larger volumes to obtain the same dose in , for example, parenteral formulations. Not only does this lead to larger syringes and packages, but also to discomfort during administration and higher production costs. From this reasoning, it follows that a protein formulation should be as concentrated as possible. Furthermore, the development of a non-parenteral dosage form, benefits that the protein concentration is as high as possible. Hence, there is a need for a formulation that allow for a high protein concentration without aggregation.

#### *PTH formulations*

Unlike other proteins that have been successfully formulated, PTH is particularly sensitive to various forms of degradation. For example, oxidation can occur at methionine residues at positions 8 and 18, giving rise to the oxidized PTH species ox-M(8)-PTH and ox-M(18)-PTH, while deamidation can occur at asparagine in position 16, giving rise to d16-PTH.

The polypeptide chain becomes truncated by breakage of peptide bonds, both at the N- and C-terminals. Furthermore, PTH may also be adsorbed to surfaces, form unspecific

aggregates and/or precipitate, thus reducing the available concentration of the drug. All these degradation reactions, and combinations thereof, leads to partial or complete loss of PTH bioactivity. A formulation of PTH must therefore prevent these degradation reactions.

5 WO 95/17207 (Holthuis et al.) discloses a PTH preparation comprising an excipient, e.g. mannitol, that co-lyophilises with PTH to yield an amorphous cake, and a non-volatile buffering agent, e.g. a citrate source. According to this disclosure, PTH is desirably incorporated in an aqueous solution in a concentration range from 25 to 250 µg/ml, preferably 50 to 150 µg/ml.

10 US 5,563,122 (Endo et al.) discloses a lyophilized composition comprising PTH(1-34), sodium chloride and a sugar. When lyophilized samples of PTH(1-34) were stored at +40°C for 3 months, it was found that preparations containing combinations of sodium chloride and sugar were more stable than control preparations which contained sodium  
15 chloride alone or sugar alone. In these experiments, each sample contained 36 µg PTH(1-34) together with 5 to 10 mg sugar and 0.1 to 1 mg NaCl.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Fig. 1

PTH stability at different protein concentrations.

Fig. 2

25 PTH stability at different pH values.

Fig. 3

PTH stability in the presence of NaCl.

## DISCLOSURE OF THE INVENTION

Contrary to the established knowledge, it has been found that relatively high concentrations of PTH can be used in a pharmaceutically acceptable formulation. The formulation may be in liquid form, but may also be lyophilized, and reconstituted prior to either single or multiple administrations. The formulation reduce discomfort during administration due to a small injection volume, while the formulation also has a pH and buffer capacity that reduce pain upon administration. The use of high PTH concentrations also offers the possibility to develop non-parenteral dosage forms, such as nasal, inhalable and oral formulations, or transdermal formulations. The possibility of a high PTH concentration also allows for a safe and economical multidose formulation, that is suitable for e.g. self-administration.

Consequently, the present invention provides in a first aspect a pharmaceutical formulation comprising human parathyroid hormone (PTH) at a concentration of or above 0.3 mg/ml, such as from 0.3 to 10 mg/ml; a pharmaceutically acceptable buffer having a pH from 4 to 6; and at least one tonicity modifier.

The term "parathyroid hormone" (PTH) encompasses naturally occurring human PTH, as well as synthetic or recombinant PTH (rPTH).

Further, the term "parathyroid hormone" encompasses full-length PTH(1-84) as well as PTH fragments. It will thus be understood that fragments of PTH variants, in amounts giving equivalent biological activity to PTH(1-84), can be incorporated in the formulations according to the invention, if desired. Fragments of PTH incorporate at least the amino acid residues of PTH necessary for a biological activity similar to that of intact PTH. Examples of such fragments are PTH (1-31), PTH(1-34), PTH(1-36), PTH(1-37), PTH(1-38), PTH(1-41), PTH(28-48) and PTH(25-39).

The term "parathyroid hormone" also encompasses variants and functional analogues of PTH. The present invention thus includes pharmaceutical formulations comprising such PTH variants and functional analogues, carrying modifications like substitutions, deletions,



insertions, inversions or cyclizations, but nevertheless having substantially the biological activities of parathyroid hormone. Stability-enhanced variants of PTH are known in the art from e.g. WO 92/11286 and WO 93/20203. Variants of PTH can e.g. incorporate amino acid substitutions that improve PTH stability and half-life, such as the replacement of methionine residues at positions 8 and/or 18, and replacement of asparagine at position 16. Cyclized PTH analogues are disclosed in e.g. WO 98/05683.

In this context, the term "biologically active" should be understood as eliciting a sufficient response in a bioassay for PTH activity, such as the rat osteosarcoma cell-based assay for PTH-stimulated adenylate cyclase production (see Rodan et al. (1983) J. Clin. Invest. 72, 1511; and Rabbani et al. (1988) Endocrinol. 123, 2709).

The PTH to be used in the pharmaceutical formulations according to the invention is preferably recombinant human PTH, such as full-length recombinant human PTH.

In preferred forms of the invention, the concentration of the said human parathyroid hormone can be 0.3 – 5 mg/ml or 0.3 – 3 mg/ml; or above 1 mg/ml, such as 1 – 10 mg/ml, 1 – 5 mg/ml; 1 – 3 mg/ml; or 1 – 2 mg/ml.

The said pharmaceutically acceptable buffer can e.g. be an acetate, a citrate, a phosphate or a carbonate buffer. Preferably, the buffer is a citrate buffer at a concentration from 5 to 20 mM. The said pharmaceutically acceptable buffer has preferably a pH between 5 and 6, most preferably around 5.5.

The said tonicity modifier can e.g. be sorbitol, glycerol, sucrose, or, preferably, sodium chloride and/or mannitol.

In a preferred form of the invention, the PTH formulation can comprise 1 to 3 mg/ml parathyroid hormone, 2 to 5 mg/ml NaCl, 20 to 50 mg/ml mannitol, 5 to 10 mM citrate buffer at a pH between 4 and 6, and optionally a preservative, such as benzyl alcohol or m-cresol.

The pharmaceutical formulations according to the invention are useful in the treatment or prevention of bone disorders, in particular osteoporosis.

- 5 In a further aspect, the present invention provides a process for the preparation of a pharmaceutical formulation as described above, said process comprising dissolving human parathyroid hormone, to a concentration from 0.3 to 10 mg/ml, and at least one tonicity modifier, in a pharmaceutically acceptable buffer having a pH between 4 and 6.
- 10 In another aspect, the invention provides the use of parathyroid hormone, at a concentration from 0.3 to 10 mg/ml, in the manufacture of a pharmaceutical formulation for the treatment or prevention of bone disorders, in particular osteoporosis, said pharmaceutical formulation in addition comprising a pharmaceutically acceptable buffer having a pH between 4 and 6, and at least one tonicity modifier.
- 15 In yet another aspect, the invention provides a method for treatment or prevention of bone related disorders, in particular osteoporosis, which comprises administering to a mammal, including man, in need of such treatment or prevention an effective amount of a pharmaceutical PTH formulation as described above.

20

## EXPERIMENTAL METHODS

- The full length human PTH(1-84) used in the formulation studies was produced and
- 25 excreted from a strain of *Escherichia coli* by known methods (see e.g. US 5,223,407, US 5,646,015 and US 5,629,205). Briefly, the human parathyroid hormone gene on plasmid pJT42 was fused with *E. coli* outer membrane protein A (*ompA*) secretion signal DNA. Also present on the plasmid is a lactose repressor gene (*lacI<sup>q</sup>*). Translation of the *ompA-rhPTH* mRNA and further processing by endogenous peptidase resulted in the production
- 30 of mature 84 amino acid human parathyroid hormone which was harvested from the bacterial culture broth.

The recombinant expression was followed by purification of PTH to a preparation essentially free of contaminants. The purification process, which involved methods known in the art (see e.g. US 5,208,041), involved cell separation, filtration, ultrafiltration, ion exchange chromatography, hydrophobic interaction chromatography, preparative reverse phase HPLC, and a second ion exchange chromatography followed by desalting to yield a liquid bulk. The resulting preparation had typically a purity of 95%, or better, as assayed by reversed-phase high performance liquid chromatography (RP-HPLC) and sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE).

Solutions of PTH were analyzed by RP-HPLC to assess concentration of PTH, purity and formation of oxidized PTH, using trifluoroacetic acid and acetonitrile in the mobile phase. Deamidated PTH was determined by cationic exchange HPLC, using a gradient of  $K^+$ . Retention times for and amounts of PTH, ox-M(8)-PTH, ox-M(18)-PTH and d16-PTH were determined using the appropriate reference standards.

The temperature effect on a rate for a process may be described by the term  $Q_{10}$ :

$$Q_{10} = \left( \frac{R_2}{R_1} \right)^{\frac{10}{T_2 - T_1}}$$

where  $R_1$  and  $R_2$  are the observed rates at temperatures  $T_1$  and  $T_2$ , respectively (*cf* Chang, R: Physical chemistry with applications to biological systems. New York, Macmillan Publishing Co., Inc., 1977; Schmidt-Nielsen K. Animal Physiology: Adaptation and environment. 3rd ed. Cambridge, Cambridge University Press, 1983). If  $Q_{10} = 2$ , then the rate doubles whenever the temperature is increased by 10 degrees; if  $Q_{10} = 3$ , then the rate triples every 10 degrees. Given that the activation energy is fairly constant for a temperature interval, most reactions and processes have a  $Q_{10}$  between 2 and 3.

Aggregation and precipitation was determined by visual inspection of the vials against a white or black background, and by comparison to a suitable reference solution. Bioactivity of PTH was measured using the rat osteosarcoma cell (UMR 106)-based assay of PTH-

stimulated adenylate cyclase production (Rodan *et al.*, J. Clin. Invest., 1983, 72:1511; Rabbiani *et al.*, Endocrinol., 1988, 123:2709).

#### 5 EXAMPLE 1 – Effect of protein concentration on PTH stability

Different concentrations of PTH were formulated in 10 mM citrate buffer. In one series of experiments, aliquots of the different formulations were lyophilized and stored at +37°C to +40°C. In another series, aliquots were stored as a liquid at +4°C. At various time points  
10 (at least three), the PTH purity were determined by rp-HPLC. Results were expressed as area-%. The data for each time series, representing different concentrations of PTH, were then normalized, by setting the PTH purity at time zero to 100%, to allow comparisons between the series. The rate of PTH loss, expressed as % per month, were calculated from the slope of the linear regression line of % PTH Vs. Time, using the formula

$$15 \quad b = \frac{n \sum xy - (\sum x)(\sum y)}{n \sum x^2 - (\sum x)^2},$$

where  $x$  corresponds to time (months) and  $y$  corresponds to % PTH purity remaining from start.

20 As shown in Fig. 1 and in Tables I and II, the stability of PTH is markedly increased, when the PTH concentration is increased, both for lyophilized (Table I) and liquid (Table II) formulations. Stability is superior at PTH concentrations above 0.3 mg/ml, both for liquid and lyophilized formulations.

#### 25 EXAMPLE 2 – pH Stability

Six different formulations were prepared consisting of PTH (0.2 mg/ml), sodium  
30 citrate/citric acid (10 mM) at pH 4, 4.5, 5, 5.5, 6 and 6.5, respectively, and mannitol (50

mg/ml). Aliquots (1 ml) were sealed in 2 ml glass vials under nitrogen and analyzed for purity of PTH by RP-HPLC.

The results are shown in Table III and in Fig. 2. Degradation was accelerated at higher temperatures, as expected for most reactions. A rough calculation of this temperature effect showed a  $Q_{10} \approx 2$  in the temperature interval from +4°C to +25°C, and  $Q_{10} \approx 3$  for the temperature interval from +25°C to +37°C, at all pH values tested. This range of  $Q_{10}$  values is consistent with other biochemical reactions, and justifies the use of the higher temperatures for accelerated degradation studies. The results indicate that the formulations at a pH from 4.5 to 5.5 have advantageous properties in terms of PTH stability. All formulations appeared as a clear colorless solution after storage. Furthermore, the formulations were stable at +4°C at a pH between 4 and 6.

### EXAMPLE 3 – Effect of ionic strength on PTH stability

Formulations were prepared consisting of PTH (0.2 mg/ml), sodium citrate/citric acid (10 mM), pH 6, and mannitol (50 mg/ml). NaCl was added to the final concentrations indicated in Fig. 3. The formulations with added NaCl were hypertonic with respect to blood plasma, in addition to having an increased ionic strength. Aliquots (1 ml) were sealed in 2 ml glass vials under nitrogen and analyzed for purity of PTH by RP-HPLC.

The results, shown in Fig. 3, indicate that at higher temperatures, a small increase in stability was obtained with increased ionic strength. At +4°C, however, the formulations were not affected by increased ionic strength in terms of PTH stability. All formulations appeared as a clear colorless solution after storage.

## EXAMPLE 4 – Effect of tonicity modifiers on PTH stability

Formulations were prepared comprising PTH (0.2 mg/ml) and sodium citrate/citric acid, pH 5.5 (10 mM), in the presence of a tonicity modifier (5% mannitol or 0.9% NaCl).

5 Aliquots (0.7 ml) were sealed under nitrogen in 3 ml glass vials. After storage at the indicated temperatures, the vials were broken and the PTH formulation analyzed for purity, oxidized PTH (ox-M(8)-PTH and ox-M(18)-PTH), deamidated PTH (d16-PTH) and bioactivity using the adenylate cyclase assay.

10 The results, shown in Table IV, show that degradation was not affected by the tonicity modifier. Bioactivity of PTH was preserved at all temperatures studied. All formulations appeared as a clear colorless solution after storage. Formation of oxidized and deamidated PTH as well as decrease in PTH concentration was negligible after 18 months at +4°C.

## EXAMPLE 5 – Effect of oxidative stress on PTH in prefilled syringes

15 Formulations were prepared comprising PTH (0.25 mg/ml), sodium citrate/citric acid, pH 5.5, (10 mM), and NaCl (9 mg/ml). Aliquots of 0.4 ml were filled into syringes fitted with a capped needle, and a rubber plunger was mounted making contact with the solution. The  
20 syringes were stored in either ambient air or in a protective nitrogen atmosphere, as indicated in Table V. The contents of the syringes were analyzed for PTH purity, oxidation and deamidation.

25 The results, shown in Table V, indicate that the presence of air does not appreciably affect neither oxidation, deamidation nor purity of PTH. Furthermore, the PTH formulations are stable at +4°C in a product container.

## EXAMPLE 6 – Effect of preservatives on PTH stability

(a)

5 Formulations were prepared comprising PTH (1.3 mg/ml), sodium citrate/citric acid, pH 5.51(10 mM) and mannitol (50 mg/ml). Some formulations in addition comprised a preservative (3 mg/ml m-cresol or 1 mg/ml EDTA).

10 Aliquots (0.5 ml) of the formulations were sealed under nitrogen in 3 ml glass vials, and stored in a refrigerator (+2°C to +8°C) or at room temperature (+20°C to +25°C). After two weeks, the formulations were assayed for PTH purity and oxidized forms of PTH by RP-HPLC.

15 The results, shown in Table VI, indicate that the formulations were not affected by m-cresol or EDTA.

(b)

20 Formulations were prepared consisting of PTH (0.8 mg/ml), sodium citrate/citric acid, pH 5.5 (10 mM) and NaCl (9 mg/ml). The preservatives m-cresol or benzyl alcohol were added to some of the formulations at a concentration of 3 mg/ml or 10 mg/ml, respectively.

25 Aliquots of 0.5 ml were sealed under nitrogen in 3 ml glass vials, and stored in an inverted position, allowing the liquid to be in contact with the rubbers stopper. Following storage at +4°C, the formulations were assayed for PTH, oxidized PTH and deamidated PTH.

The results are shown in Table VII. Stability of PTH in the presence of m-cresol was comparable to that of control. In the presence of benzyl alcohol, the stability of PTH decreased, mostly attributable to the formation of M8 and M18 oxidized forms of PTH.

30 The concentration of PTH after storage was not affected by the presence of preservative (data not shown). Previous experiments have shown that the bioactivity of PTH is not

affected by the presence of these preservatives. Furthermore, these preservatives gave a satisfactory protection against microbial growth after challenge, according to methods described in U.S. Pharmacopeia and European Pharmacopeia (data not shown). In the tested formulations, PTH is stable in the presence of efficient preservatives, thus allowing  
5 for the use of the formulation in a multidose product.

0040042960



TABLE I

PTH stability in lyophilized formulations

Formulation	1A	1B	1C	1D	1E	1F	1G	1H
PTH (mg/ml)	0.072	0.1	0.2	0.5	1.5	3	5	5
mannitol (mg/ml)	50	35	35	35	50	50	50	50
NaCl (mg/ml)	0	0	0	0	1.2	2.4	0	4.5
Temperature (°C)	40	37	37	37	40	37	37	37
pH	5.5	6	6	6	5.5	5.5	5.5	5.5
fill volume (ml)	0.5	0.7	0.7	0.7	1	0.5	0.4	0.4
Month	% PTH remaining from start							
0	100	100	100	100	100	100	100	100
1	n.d.	99.28	98.08	99.28	99.60	99.60	99.76	99.86
2	98.48	n.d.	n.d.	n.d.	99.45	99.50	99.39	99.29
3	97.44	100.21	99.50	100.00	98.75	99.00	n.d.	n.d.
4	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	99.29	98.99
6	n.d.	92.97	94.96	98.46	n.d.	98.35	n.d.	n.d.
9	n.d.	89.87	91.53	95.80	n.d.	n.d.	n.d.	n.d.
12	n.d.	87.49	90.42	96.93	n.d.	n.d.	n.d.	n.d.
	Degradation rate							
% per month	0.84	1.15	0.84	0.32	0.39	0.27	0.13	0.21

n.d. = not determined

TABLE II

PTH stability in liquid formulations

Formulation	2A	2B	2C	2D	2E	2F	2G	2H
PTH (mg/ml)	0.2	0.2	0.2	0.2	0.2	0.25	0.5	0.78
Mannitol (mg/ml)	50	50	50	0	0	0	50	0
NaCl (mg/ml)	0	0	0	9	9	9	2	9
Temperature (°C)	4	4	4	4	4	4	4	4
pH	5	5.5	5.5	5	5.5	5.5	5.5	5.5
Fill volume (ml)	0.7	0.7	0.7	0.7	0.7	0.4	1.1	1
Month	% PTH remaining from start							
0	100	100	100	100	100	100	100	100
1	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	100.10	n.d.
2	101.03	100.20	100.10	101.23	101.44	n.d.	n.d.	n.d.
3	n.d.	n.d.	n.d.	n.d.	n.d.	100.15	99.20	99.60
4	100.62	99.29	99.80	100.31	97.42	n.d.	n.d.	n.d.
5	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
6	100.21	99.29	99.28	100.21	100.72	98.43	99.00	99.05
9	97.54	96.84	98.98	100.00	97.32	n.d.	n.d.	n.d.
12	97.43	96.22	96.12	96.71	96.39	n.d.	n.d.	n.d.
18	93.94	93.40	92.77	95.97	95.52	n.d.	n.d.	n.d.
	Degradation rate							
% per month	0.38	0.39	0.41	0.28	0.30	0.26	0.19	0.16

n.d. = not determined

TABLE III

PTH stability at different pH values

Storage	Temp.	pH					
		4	4.5	5	5.5	6	6.5
		% PTH remaining from start					
Initial		98.9	99	99	99	99	99
2 weeks	+37°C	90.5	92	92	92	90	90
2 months	+25°C	92.6	94	94	94	92	91
2 months	+37°C	73.2	78	78	76	70	68
6 months	+4°C	98.5	98	98	98	98	97
6 months	+25°C	82.6	88	89	87	79	74
10 months	+4°C	96.8	<i>n.d.</i>	97	98	<i>n.d.</i>	95

n.d. = not determined

TABLE IV

PTH stability in the presence of tonicity modifiers

		PTH 1-84 Purity (%)	PTH 1-84 (µg/ml)	M8 (%)	M18 (%)	d16-PTH (%)	Bioactivity
Start	mannitol	98.0	207	0.6	1.3	n.d.	0.64
	NaCl	96.9	209	1.0	1.7	n.d.	0.78
3 months +37°	mannitol	65.4	137	7.9	11	24	1.15
	NaCl	70.8	156	8.1	9.4	21	0.89
6 months +25°	mannitol	72.2	155	4.8	4.8	5.5	0.57
	NaCl	74.6	159	6.2	6	6.0	0.39
18 months +4°	mannitol	91.5	204	1.2	2.1	0.4	0.4
	NaCl	92.6	200	1.5	2.4	0.6	0.27

n.d.: not detected; M8 = ox-M(8)-PTH; M18 = ox-M(18)-PTH

TABLE V

PTH stability in the presence of air

		PTH 1-84 Purity (%)	PTH 1-84 (µg/ml)	M8 (%)	M18 (%)	d16-PTH (%)
Start		99.1	0.24	0.14	0.36	0.06
3 months +25°C	air	84.2	0.22	3.9	4.6	<d.l.
	nitrogen	82.5	0.22	3.2	3.7	<d.l.
3 months +13°C	air	96.7	0.23	0.84	1.0	0.59
	nitrogen	n.d.	n.d.	n.d.	n.d.	n.d.
4 months +4°C	air	97.5	n.d.	0.77	1.0	0.32
	nitrogen	97.8	n.d.	0.59	0.88	0.36

&lt;d.l. = below detection level; n.d. = not determined; M8 = ox-M(8)-PTH;

M18 = ox-M(18)-PTH

TABLE VI

PTH stability in the presence of preservatives

		rhPTH(1-84) Purity (%)	M8 (%)	M18 (%)
Control	Refr.	99.7	0.06	0.23
	RT	99.6	0.17	0.23
m-cresol	Refr.	99.6	0.14	0.23
	RT	99.3	0.27	0.39
EDTA	Refr.	99.7	0.11	0.24
	RT	99.4	0.27	0.34

Refr. = Refrigerator; RT = Room temperature; M8 = ox-M(8)-PTH; M18 = ox-M(18)-PTH

TABLE VII

PTH stability in the presence of preservatives

	Months	rhPTH(1-84) (%)	M8 (%)	M18 (%)	dPTH (%)
Control	0	99.5	0.1	0.2	0.1
	3	99.1	0.2	0.3	0.2
	6	98.5	0.4	0.2	0.2
m-cresol	0	99.3	0.1	0.3	<d.l.
	3	99.2	0.1	0.3	<d.l.
	6	98.7	0.2	0.3	<d.l.
benzyl alcohol	0	99.0	0.2	0.5	0.1
	3	92.9	3.0	3.8	0.2
	6	92.4	3.1	3.8	0.2

&lt;d.l. = below detection level; M8 = ox-M(18)-PTH; M18 = ox-M(18)-PTH


## CLAIMS

1. A pharmaceutical formulation comprising human parathyroid hormone at a concentration of or above 0.3 mg/ml to 10 mg/ml; a pharmaceutically acceptable  
5 buffer having a pH from 4 to 6, and at least one tonicity modifier.
2. The formulation according to claim 1 wherein the said human parathyroid hormone is human recombinant parathyroid hormone.
- 10 3. The formulation according to claim 1 to 2 wherein the said human parathyroid hormone is full-length parathyroid hormone.
4. The formulation according to any one of claims 1 to 3 wherein the concentration of the said human parathyroid hormone is from 0.3 mg/ml to 5 mg/ml.
- 15 5. The formulation according to claim 4 wherein the concentration of the said human parathyroid hormone is from 1 mg/ml to 3 mg/ml.
6. The formulation according to any one of claims 1 to 5 wherein the said  
20 pharmaceutically acceptable buffer is a citrate buffer at a concentration from 5 to 20 mM.
7. The formulation according to any one of claims 1 to 6 wherein the said pharmaceutically acceptable buffer has a pH between 5 and 6.
- 25 8. The formulation according to any one of claims 1 to 7 wherein the said tonicity modifier is sodium chloride and/or mannitol.
9. The formulation according to any one of claims 1 to 8 comprising 1 to 3 mg/ml  
30 parathyroid hormone, 2 to 5 mg/ml NaCl, 20 to 50 mg/ml mannitol, 5 to 10 mM citrate buffer at a pH between 4 and 6, and optionally a preservative.

10. The formulation according to any one of claims 1 to 9 in liquid form.
11. The formulation according to any one of claims 1 to 9 in lyophilized form.
- 5 12. A process for the preparation of a pharmaceutical formulation according to any one of claims 1 to 11, comprising dissolving human parathyroid hormone, to a concentration from 0.3 to 10 mg/ml, and at least one tonicity modifier, in a pharmaceutically acceptable buffer having a pH between 4 and 6.
- 10 13. A pharmaceutical formulation according to any one of claims 1 to 11 for use in the treatment or prevention of bone disorders.
14. A pharmaceutical formulation according to any one of claims 1 to 11 for use in the  
15 treatment or prevention of osteoporosis.
15. Use of parathyroid hormone at a concentration from 0.3 to 10 mg/ml, in the  
manufacture of a pharmaceutical formulation for the treatment or prevention of bone  
disorders, said pharmaceutical formulation in addition comprising a pharmaceutically  
20 acceptable buffer having a pH between 4 and 6, and at least one tonicity modifier.
16. The use according to claim 15 for the treatment or prevention of osteoporosis.
17. A method for treatment or prevention of bone related disorders which comprises  
25 administering to a mammal, including man, in need of such treatment or prevention an effective amount of a formulation according to any one of claims 1 to 11.
18. The method according to claim 17 for treatment or prevention of osteoporosis.

1/3


Fig. 1






2/3

Fig. 2



3/3

Fig. 3



LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROSIN	Reg. No. 25,735
JOHNNY A. KUMAR	Reg. No. 34,649
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
BERNHARD D. SAXE	Reg. No. 28,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
HAROLD C. WEGNER	Reg. No. 25,258

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Stephen A. Bent  
FOLEY & LARDNER  
Washington Harbour  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109

Telephone: (202) 672-5404  
 Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	<u>Martin Billger</u>
Residence	<u>S-431 83 Molndal, SWEDEN</u> <i>SEX</i>
Citizenship	<u>Sweden</u>
Post Office Address	<u>Astra Hassle AB, S-431 83 Molndal, SWEDEN</u>
Inventor's signature	<u><i>Martin Billger</i></u>
Date	<u>12-12-2000</u>

200 Name of second inventor

Mikael Brulls

Residence

S-431 83 Molndal, SWEDEN *SEX*

Citizenship

Sweden

Post Office Address

Astra Hassle AB, S-431 83 Molndal, SWEDEN

Inventor's signature

Mikael Brulls

Date

December 12, 2000

HFC

**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**PROTEIN FORMULATIONS**

(Attorney Docket No. 016777/0436)

the specification of which (check one)

\_\_\_\_\_ is attached hereto.

  X   was filed on April 26, 1999 as United States Application Number \_\_\_\_\_ or PCT International Application Number PCT/CA99/00376 and was amended on \_\_\_\_\_ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number
981495-4		4/28/1998	

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,163
WILLIAM T. ELLIS	Reg. No. 26,874
JOHN J. FELDHAUS	Reg. No. 28,822
PATRICIA D. GRANADOS	Reg. No. 33,683
JOHN P. ISACSON	Reg. No. 33,715
MICHAEL D. KAMINSKI	Reg. No. 32,904